Agomab shareholders approved Marino Garcia and Dr. Naimish Patel as non-executive directors on September 11, 2026, while also approving consolidation and split adjustment of outstanding pre-IPO warrants. Investors gain two board appointments and a Warrant structure aligned with the share split used in connection with the IPO.

Key Highlights

  • Agomab said both directors bring complementary experience to its board.
  • Shareholders approved all resolutions considered at the Special and Extraordinary General Shareholders’ Meeting.
  • The approved warrant resolution covered outstanding pre-IPO warrants.

Investors approved a consolidation and split adjustment covering outstanding pre-IPO warrants. The resolutions were approved at a Special and Extraordinary General Shareholders’ Meeting, where shareholders backed every proposal submitted for consideration. Chief Executive Officer Tim Knotnerus said their experience would support the company as it advances potential disease-modifying therapies. Garcia said he expected to work with the board and management on Agomab (NASDAQ: AGMB)’s strategy and long-term vision.

Pre-IPO Warrants Adjusted to Share Split

The warrant resolution covers outstanding instruments issued before the company’s IPO. Patel said he would contribute experience in translational medicine and clinical development.